本帖最后由 老马 于 2012-1-13 21:20 编辑 4 w. r0 s2 c P) \5 x! |
3 M% b, b' w, @爱必妥和阿瓦斯丁的比较% x$ ^8 z' g5 W3 ^5 h
6 d7 ^ q. j, e4 C: fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 {* e6 f5 ?( q- K3 k
- t2 f" ]5 g& ~- l8 _5 W
6 O( T6 L+ M3 Khttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. S% y$ D6 ]2 `% P5 S* Y" `==================================================
! y V6 t" m# k$ {( g$ r2 wOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)* z9 E6 B& W. U1 v/ f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) ?+ w- `" s, C- J, p/ {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ B! V3 b; S& @! \ D
|